Sign up to get updates from us
Can T cells be leveraged as a cancer therapeutic? Check. How about natural killer (NK) cells? Check. Now meet invariant natural killer (iNKT) cells – a potentially game-changing tool to reprogram the innate and adaptive immune system to recognize and attack tumors. In this episode of the Benchtop Bios Podcast, leading life science entrepreneur and former Executive Director at Bristol-Myers Squibb, Dr. Ian Walters – now CEO of Portage Biotech – highlights the role iNKT cells play in activating the immune system and how Portage is leveraging these cells to advance novel cancer treatments.
